Listenly

What is the compound annual growth rate forecast for biological CDMO manufacturing over the next seven years?

Answered at 6:34 in Why Procurement Can Make or Break a Drug Company · Executive Edge Podcast

— questions searchable right now

What is the compound annual growth rate forecast for biological CDMO manufacturing over the next seven years?

The CDMO marketplace is hundreds of billions in total, and biologics manufacturing is forecasted to grow at a compound annual growth rate of 8 to 12% over the next seven years, reflecting rapid growth in the global manufacturing of these drugs.

Dave Stowe on Executive Edge PodcastAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

The CDMO marketplace is hundreds of billions in total, and biologics manufacturing is forecasted to grow at a compound annual growth rate of 8 to 12% over the next seven years, reflecting rapid growth in the global manufacturing of these drugs.

Dave Stowe, Founder and Managing Partner at Adventus · Why Procurement Can Make or Break a Drug Company · Executive Edge Podcast · answer at 6:34

Key takeaways

  • The CDMO marketplace is hundreds of billions in total, and biologics manufacturing is forecasted to grow at a compound annual growth rate of 8 to 12% over the next seven years, reflecting rapid growth in the global manufacturing of these drugs.

Quote to remember

“There's always this challenge, right? It's a game of capacity management. You know, you can imagine you're buying capacity at the CDMO. They could sell it to somebody else.”

— Dave Stowe

The full answer · about 1 min

The CDMO marketplace is hundreds of billions in total, and biologics manufacturing is forecasted to grow at a compound annual growth rate of 8 to 12% over the next seven years, reflecting rapid growth in the global manufacturing of these drugs.

Key facts

  • 37% of global chemicals in pharmaceutical manufacturing originate from China
  • CDMO biologics manufacturing forecasted at 8 to 12% compound annual growth rate over seven years
  • Drug development timeline: 2 to 5 to 10 years from preclinical through full production
  • Radioisotope half-life example: 5-day half-life requiring overnight shipping from Indiana to patient administration
  • Injectable syringe viscosity requirement: under 5 to 10 milliliters

People, companies and topics mentioned

AdventusCDMO (Contract Development Manufacturing Organization)FDA (Food and Drug Administration)PwCOliver WymanHorizon TherapeuticsPurdue PharmaKSM (Key Starting Materials)

More answers from this episode

 ·  All answers from Executive Edge Podcast →
—
—
0:00
0:00